Recent Update on Bacteria as a Delivery Carrier in Cancer Therapy: From Evil to Allies Bacteria as a Carrier in Cancer Therapy

• Published in: Pharmaceutical research Vol. 39; no. 6; pp. 1115 - 1134
• Main Authors: Pandey, Manisha, Choudhury, Hira, Vijayagomaran, Prathiba A/P, Lian, Pauline Ng Poh, Ning, Tan Jing, Wai, Ng Zing, Xian-Zhuang, Ng, Le Er, Chong, Rahmah, Nur Suraiza Nabila, Kamaruzzaman, Nur Dayana Binti, Mayuren, Jayashree, Candasamy, Mayuren, Gorain, Bapi, Chawla, Pooja A., Amin, Mohd Cairul Iqbal Mohd
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2022
• Subjects: Biochemistry; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Expert Review; Medical Law; Pharmacology/Toxicology; Pharmacy; therapeutic carrier for chemotherapy; cancer treatment; drug delivery; bacteria-assisted therapy
• ISSN: 0724-8741; 1573-904X
• DOI: 10.1007/s11095-022-03240-y

Cancer is associated with a comprehensive burden that significantly affects patient’s quality of life. Even though patients’ disease condition is improving following conventional therapies, researchers are studying alternative tools that can penetrate solid tumours to deliver the therapeutics due to issues of developing resistance by the cancer cells. Treating cancer is not the only the goal in cancer therapy; it also includes protecting non-cancerous cells from the toxic effects of anti-cancer agents. Thus, various advanced techniques, such as cell-based drug delivery, bacteria-mediated therapy, and nanoparticles, are devised for site-specific delivery of drugs. One of the novel methods that can be targeted to deliver anti-cancer agents is by utilising genetically modified non-pathogenic bacterial species. This is due to the ability of bacterial species to multiply selectively or non-selectively on tumour cells, resulting in biofilms that leads to disruption of metastasis process. In preclinical studies, this technology has shown significant results in terms of efficacy, and some are currently under investigation. Therefore, researchers have conducted studies on bacteria transporting the anti-cancer drug to targeted tumours. Alternatively, bacterial ghosts and bacterial spores are utilised to deliver anti-cancer drugs. Although in vivo studies of bacteria-mediated cancer therapy have shown successful outcome, further research on bacteria, specifically their targeting mechanism, is required to establish a complete clinical approach in cancer treatment. This review has focused on the up-to-date understanding of bacteria as a therapeutic carrier in the treatment of cancer as an emerging field.